PIM
REGN icon

Plato Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Plato Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Buy
3,983
+464
+13% +$316K 0.14% 157
2026
Q1 		$2.72M Hold
3,519
– – 0.18% 125
2025
Q4 		$2.73M Buy
3,519
+33
+0.9% +$22.4K 0.18% 120
2025
Q3 		$1.95M Sell
3,486
-293
-8% -$166K 0.13% 172
2025
Q2 		$1.98M Buy
3,779
+2
+0.1% +$1.12K 0.15% 154
2025
Q1 		$2.42M Buy
3,777
+1,116
+42% +$768K 0.2% 121
2024
Q4 		$1.9M Buy
2,661
+44
+2% +$36.9K 0.14% 159
2024
Q3 		$2.75M Buy
2,617
+79
+3% +$87.9K 0.22% 113
2024
Q2 		$2.67M Buy
2,538
+144
+6% +$140K 0.25% 94
2024
Q1 		$2.3M Buy
2,394
+2,271
+1,846% +$2.16M 0.24% 109
2023
Q4 		$108K Buy
+123
New +$101K 0.13% 150

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Plato Investment Management's REGN Position: Q2 2026 in Review

Plato Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 13% in Q2 2026, buying an estimated $316K and bringing the position to 3,983 shares worth $2.47M. The position accounts for 0.14% of the portfolio, ranked #157.

Plato Investment Management first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.75M in Q3 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Plato Investment Management held 3,983 shares of Regeneron Pharmaceuticals worth $2.47M as of Q2 2026.
  • Plato Investment Management bought 464 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $316K.
  • Regeneron Pharmaceuticals made up 0.14% of Plato Investment Management's portfolio in Q2 2026, its #157 holding.
  • Plato Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Plato Investment Management's Regeneron Pharmaceuticals position peaked at $2.75M in Q3 2024.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Plato Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.